| 前收盘价格 | 8.98 |
| 成交量 | 66,955 |
| 预期市盈率 (P/E Forward) | 12.15 |
| 价格/销量 (P/S) | 5.62 |
| 股市价格/股市净资产 (P/B) | 4.62 |
| 52周波幅 |
| 营业毛利率 | 9.01% |
| 营业利益率 (TTM) | 4.99% |
| 稀释每股收益 (EPS TTM) | 0.220 |
| 季度收入增长率 (YOY) | 26.80% |
| 季度盈利增长率 (YOY) | 897.30% |
| 总债务/股东权益 (D/E MRQ) | 8.73% |
| 流动比率 (MRQ) | 5.03 |
| 营业现金流 (OCF TTM) | 12.13 M |
| 杠杆自由现金流 (LFCF TTM) | 3.66 M |
| 资产报酬率 (ROA TTM) | 1.42% |
| 股东权益报酬率 (ROE TTM) | 7.41% |
新闻情绪
AIStockmoo 评分
| 价值 30% | 3.2 |
| 相对其盈利增长,估值偏低。 参考 | |
| 资本回报低于资本成本。资本回报上升。 参考 | |
| 负债低。盈利能力弱。短期流动性充足。现金流为正。 参考 | |
| 来自我们的 AI Insight 报告对预期回报与风险的评估。 参考 | NA |
| 隐含增长 参考 | NA |
| 历史估值 参考 | NA |
| 持仓估值 参考 | NA |
| 风险溢价 参考 | NA |
| 市场估值 参考 | NA |
| 时机 30% | -3.2 |
| 过去一年呈上升趋势。股价远低于52周高点。 参考 | |
| 下降趋势:股价位于均线之下,均线向下。股价已大幅低于均线。下跌日成交量较大。 参考 | |
| 来自我们对走势图的 AI 技术分析。 参考 | NA |
| 市场情绪 20% | 1.4 |
| 近期没有目标价,因此依据目标价的调整方向。 参考 | |
| 近期新闻大多正面。 参考 | |
| 持仓情绪 参考 | NA |
| 聪明钱 20% | 1.2 |
| 机构在最新13F申报中净+0.96%的股份:32家增持,27家减持(截至30 Sep 2026的季度)。 参考 | |
| 空头持仓从31 Aug到30 Oct 2026变化-4.2%,回补天数2.5天(FINRA)。 参考 | |
| 内部交易活动 参考 | NA |
| 市场和行业状况不佳。 | |
| 市场环境偏谨慎。 参考 | |
| 行业表现落后大市。 | |
| 各支柱方向不一,评分因此减弱。 | |
| 不计入评分 | |
| 近期出现看涨反转形态:倒锤子线。 参考 | |
| 低于中期趋势线。 参考 | |
| 股价低于其52周平均水平。5年来上涨。 参考 | |
| 短、中、长期趋势均向下。短期动能下降。 参考 | |
| 支撑与阻力没有明确信号。 参考 | |
| 最终评分 | 0.40 |
市场趋势
| 短期 | 中期 | ||
| 行业 | Medical Devices (US) | 混合的 | 混合的 |
| Medical Devices (全球的) | 混合的 | 混合的 | |
| 股票 | Brainsway Ltd. | 混合的 | 看跌 |
相关股票
| 股票 | 市值 | DY | P/E(TTM) | P/B | 评分 |
|---|---|---|---|---|---|
| BWAY | - | - | - | 4.62 | 0.4 |
| TNDM | - | - | - | 8.81 | -1.4 |
| SSII | - | - | - | 6.11 | -2.0 |
| QTI | - | - | - | 9.14 | -5.0 |
| AXGN | - | - | - | 6.12 | 0.0 |
| ESTA | - | - | - | 128.59 | -1.7 |
|
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems. |
|
| 部门 | Healthcare |
| 行业 | Medical Devices |
| 投资方式 | Small Growth |
| 内部持股比例 | 6.40% |
| 机构持股比例 | 32.27% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Valor Management Llc | 30 Sep 2026 | 5,314,950 |
| Masters Capital Management Llc | 30 Sep 2026 | 1,246,099 |
| Essex Investment Management Co Llc | 30 Sep 2026 | 574,818 |
| Cresset Asset Management, Llc | 30 Sep 2026 | 314,924 |
| Hwg Holdings Lp | 30 Sep 2026 | 253,050 |
| Y.D. More Investments Ltd | 30 Sep 2026 | 224,382 |
| Eagle Global Advisors Llc | 30 Sep 2026 | 182,606 |
| Legato Capital Management Llc | 30 Sep 2026 | 176,569 |
| Ark Investment Management Llc | 30 Sep 2026 | 146,850 |
| Sei Investments Co | 30 Sep 2026 | 119,717 |
| Walleye Capital Llc | 30 Sep 2026 | 106,834 |
该时间范围内无数据。
该时间范围内无数据。
机构
机构持股比例: 28.39%
| 持仓变动 | 机构数 | 股数 |
|---|---|---|
| 增持 | 32 | 715,233 |
| 减持 | 27 | 782,187 |
| 新建仓 | 20 | 567,025 |
| 清仓 | 8 | 116,475 |
来源:经Nasdaq的SEC 13F申报,最新申报截至30 Sep 2026。申报在每季结束后45天内陆续提交。
空头持仓
| 结算日 | 股数 | 回补天数 |
|---|---|---|
| 30 Oct 2026 | 199,353 | 2.5 |
| 15 Oct 2026 | 226,033 | 1.7 |
| 30 Sep 2026 | 250,485 | 2.8 |
| 15 Sep 2026 | 199,566 | 2.2 |
| 31 Aug 2026 | 208,111 | 2.5 |
| 14 Aug 2026 | 156,367 | 1.0 |
来源:经Nasdaq的FINRA空头持仓数据,每月公布两次。
| 日期 | 类型 | 细节 |
|---|---|---|
| 10 Nov 2026 | Yahoo Finance |
BrainsWay Ltd (BRSYF) (Q3 2026) Earnings Call Highlights: Revenue Jumps 34% as Margins Expand ...
BrainsWay Ltd (BRSYF) posted $18.1 million in Q3 2026 revenue, doubled operating income to $2.6 million, and signaled full-year results at the high end of guidance on strong SWIFT and OCD demand. |
| 10 Nov 2026 | Yahoo Finance |
What Brainsway (BWAY) Said on Its Q3 Earnings Call
Brainsway (NASDAQ:BWAY) reported 34% revenue growth and a more than doubling of operating income in the third quarter of 2026, as shipments of its Deep TMS systems increased and reimbursement coverage expanded for its accelerated treatment protocol. The company expects full-year results to land at… |
| 10 Nov 2026 | Yahoo Finance |
BrainsWay Reports Third Quarter 2026 Financial Results and Operational Highlights
Revenue increased 34% to $18.1 million in Q3 2026; Operating income rose 107% to $2.6 million and Adjusted EBITDA rose approximately 92% to $3.9 million Remaining performance obligations grew 31% year-over-year to approximately $85 million Shipped 130 Deep TMS systems in Q3 2026, a 44% increase… |
| 02 Nov 2026 | Yahoo Finance |
BrainsWay Announces Strategic Collaboration with Mindful Health Solutions
Latest Collaboration Comes Amid Progress in Other Strategic Initiatives, Including Follow-on Investment in Earlier Minority Stake Investment TargetBURLINGTON, Mass. and JERUSALEM, Nov. 02, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader… |
| 28 Oct 2026 | Yahoo Finance |
BrainsWay to Report Third Quarter 2026 Financial Results on November 10, 2026
BURLINGTON, Mass. and JERUSALEM, Oct. 28, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced non-invasive neurostimulation treatments for mental health disorders, today announced that it will report its third quarter 2026… |
| 26 Oct 2026 | Yahoo Finance |
BrainsWay Expands U.S. Insurance Coverage for Deep TMS™ Treatment of OCD to Over 118 Million Lives
BURLINGTON, Mass. and JERUSALEM, Oct. 26, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced further expansion in the number of medical policies across the U.S.… |
| 19 Oct 2026 | Yahoo Finance |
BrainsWay Announces Strategic Collaboration with Inland Psychiatry Medical Group
Partnership with Established Southern California Behavioral Health Provider Aims to Accelerate Innovative Application of Interventional Psychiatry TreatmentsBURLINGTON, Mass. and JERUSALEM, Oct. 19, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a… |
| 13 Oct 2026 | Yahoo Finance |
BrainsWay Reports Rise in Favorable Accelerated Deep TMS™ Coverage to Over 70 Million Covered Lives
BURLINGTON, Mass. and JERUSALEM, Oct. 13, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced further expansion in the number of medical policies across the U.S.… |
| 10 Sep 2026 | Yahoo Finance |
BrainsWay’s (BWAY) Growth Streak Just Got Harder To Ignore
On August 12, BrainsWay Ltd. (NASDAQ:BWAY) reported second-quarter 2026 results that make the neurostimulation company look less like a niche medtech story and more like a genuine growth compounder. Revenue climbed 35% year over year to a record $17.1 million, and adjusted EBITDA more than doubled… |
| 09 Sep 2026 | Yahoo Finance |
Are Options Traders Betting on a Big Move in Brainsway Stock?
Investors need to pay close attention to BWAY stock based on the movements in the options market lately. |
| 08 Sep 2026 | Yahoo Finance |
BrainsWay Reports Promising Pilot Study Results in Patients with Depression and Comorbid Early-Stage Alzheimer’s Disease Treated with Deep TMS™
Peer-reviewed pilot study shows 83.3% response rate and 50% remission rate in depressive symptoms, alongside measurable neurophysiological changes in brain activity and connectivity BURLINGTON, Mass. and JERUSALEM, Sept. 08, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY), a global… |
| 27 Aug 2026 | Yahoo Finance |
Wall Street Analysts See a 30.07% Upside in Brainsway (BWAY): Can the Stock Really Move This High?
The mean of analysts' price targets for Brainsway (BWAY) points to a 30.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
| 27 Aug 2026 | Yahoo Finance |
BrainsWay Deep TMS™ Study Shows 70% Reduction in Patients Experiencing Suicidal Ideation
Peer-reviewed secondary analysis adds to growing body of clinical evidence supporting the potential role of Deep TMS in addressing suicidal ideation among patients with major depressive disorderBURLINGTON, Mass. and JERUSALEM, Aug. 27, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY)… |
| 显示更多 | ||
近期信号 K线形态与EMA交叉
技术形态 中期
AI 技术分析
投资组合